Astellas Venture Management LLC

Astellas Venture Management (AVM) is the wholly-owned venture capital organization within Astellas Pharma, dedicated to supporting pre-clinical, cutting-edge science that can bring value to patients. With over 20 years of experience, AVM provides equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them advance their innovations faster. AVM operates as a strategic investor, focusing on science that enhances the current Astellas R&D pipeline or catalyzes new directions in discovery research. Their investment approach is grounded in a "Pharma View," leveraging their extensive experience in the pharmaceutical industry to provide portfolio companies with invaluable information and expertise to support their growth. Furthermore, AVM can facilitate dialogue between its portfolio companies and Astellas Pharma for potential future collaborations. AVM targets privately owned early-stage biotechnology companies focused on therapeutics programs and platform technologies for drug discovery and development. To be considered for equity investment, the program stage should be in the preclinical phase. Their areas of interest align with the innovative therapeutic approaches that mirror Astellas Pharma's R&D strategy, particularly those addressing unmet medical needs and offering unprecedented treatments that are likely to be realized in the near future. AVM differentiates itself by providing portfolio companies with a "Pharma View" derived from its long-standing experience in the pharmaceutical industry. This provides portfolio companies with invaluable information and pharma expertise to support their growth. They also facilitate dialogue between portfolio companies and Astellas Pharma, fostering opportunities for future collaborations.

Therapeutic programs, platform technologies for drug discovery and development

Core thematic spaces, technologies, and target market segments of interest.